Heart Diseases D006331

Diseases [C] » Cardiovascular Diseases [C14] » Heart Diseases

Description

Pathological conditions involving the HEART including its structural and functional abnormalities.   MeSH

Subtype Terms (28)

Arrhythmias, Cardiac
106 drugs (78 approved, 28 experimental)

Carcinoid Heart Disease
2 approved drugs

Cardiac Conduction System Disease
 

Cardiac Output, High
 

Cardiac Output, Low
18 drugs (11 approved, 7 experimental)

Cardiac Tamponade
 

Cardiomegaly
5 drugs (4 approved, 1 experimental)

Cardiomyopathies
110 drugs (60 approved, 50 experimental)

Cardiotoxicity
62 drugs (54 approved, 8 experimental)

Endocarditis
32 drugs (30 approved, 2 experimental)

Heart Aneurysm
 

Heart Arrest
64 drugs (56 approved, 8 experimental)

Heart Defects, Congenital
86 drugs (67 approved, 19 experimental)

Heart Failure
444 drugs (229 approved, 215 experimental)

Heart Neoplasms
 

Heart Rupture
 

Heart Valve Diseases
62 drugs (46 approved, 16 experimental)

Myocardial Ischemia
181 drugs (121 approved, 60 experimental)

Myocardial Stunning
11 drugs (9 approved, 2 experimental)

Pericardial Effusion
2 approved drugs

Pericarditis
6 drugs (5 approved, 1 experimental)

Pneumopericardium
 

Post-Cardiac Arrest Syndrome
10 approved drugs

Postpericardiotomy Syndrome
1 approved drug

Pulmonary Heart Disease
1 approved drug

Rheumatic Heart Disease
8 drugs (6 approved, 2 experimental)

Ventricular Dysfunction
10 drugs (8 approved, 2 experimental)

Ventricular Outflow Obstruction
5 approved drugs


Phase 4 Indicated Drugs (88)

Phase 3 Indicated Drugs (113)


Organization Involved with Phase 4 Indications (168)

Organization Involved with Phase 3 Indications (199)

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

National Institute of Neurological Disorders and Stroke (NINDS)

National Institute on Aging (NIA)

National Institutes of Health (NIH)

New England Research Institutes

New York Medical College

New York University

Northwell Health

Northwestern University

Novo Nordisk

Novosibirsk Research Institute of Circulation Pathology

NSABP Foundation

Office of Dietary Supplements (ODS)

Ogden Research Foundation

Oklahoma Medical Research Foundation

Oregon Health and Science University

Oswaldo Cruz Foundation

Pacific Health Research Institute

Palo Alto Medical Research Foundation

Papworth Hospital NHS Foundation Trust

Parke-Davis

Queen's University, Belfast

Rajaie Cardiovascular Medical and Research Center

Red de Investigación en Servicios de Salud en Enfermedades Crónicas (REDISSEC)

Rhode Island Hospital

Roche

Rush University

Rutgers University

RWTH Aachen University

Salt Lake Clinic Research Foundation

Santa Rosa Medical Center

Scios

Servicio de Evaluación. Servicio Canario de Salud. Spain

Siriraj Hospital

Smt. Kashibai Navale Medical College and General Hospital

Solae, LLC

Spanish Clinical Research Network

State University of New York

Statistics and Epidemiology Research Corporation

St. Joseph Hospital Health Center

St. Louis University

Syneos Health

The 1991 Pharmacy Foundation

The Christie NHS Foundation Trust

The Cleveland Clinic

The Medicines Company

Tufts University

United States Army

Universidad Complutense de Madrid

Universidad del Norte, Barranquilla

Organization Involved with Phase 2 Indications (73)

Organization Involved with Other Experimental Indications (54)

Hierarchy Tree View

UMLS Data


YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.